3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
2
Head & Neck
1
Conditions
Head and Neck Neoplasms
4
Recurrence
3
Neoplasm Metastasis
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Nasopharyngeal Carcinoma
2
Mouth Neoplasms
2
Uveal Melanoma
1
Urologic Neoplasms
1
Soft Tissue Neoplasms
1
Sarcoma
1
Pharyngeal Neoplasms
1
Oropharyngeal Neoplasms
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Neoplasms
1
Multiple Acyl Coenzyme A Dehydrogenase Deficiency
1
Melanoma
1
Lymphangioleiomyomatosis
1
Erdheim-Chester Disease
1
Epstein-Barr Virus Infections
1
Endocrine Gland Neoplasms
1
Castleman Disease
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
2
utomilumab
1
tislelizumab
1
spartalizumab
1
pentetreotide
1
pembrolizumab
1
fludarabine phosphate
1
entinostat
1
cemiplimab
1
Valproic Acid
1
Toll-Like Receptor 1
1
Specimen Handling
1
Magnetic Resonance Spectroscopy
1
LY2940680
1
Interleukin-2
1
Interleukin-13
1
Fluorodeoxyglucose F18
1
Cryosurgery
1
Biopsy
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
Valproic Acid
×
Head & Neck
×
Clear all
NCT04729543
2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2
Recruiting
20 enrolled